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researchers, and clinicians. Two focus groups containing eight to
ten patients who met the inclusion criteria for insomnia (diagno-
sis, history) were surveyed. A preliminary instrument containing
42 items (scale: 1 = not important at all to 5 = extremely impor-
tant), including demographic characteristics and co-morbidities,
was developed and then pretested in 14 additional patients prior
to validation testing. RESULTS: Currently, 109 patients have
participated in the testing of the instrument (mean age 50 + 11.5
years, 67.9% female). Principal components exploratory factor
analysis (KMO = 0.85) reduced the instrument to 17 items
(Cronbach á = 0.90) in 5 domains. Cronbach á for the 5 domains
(contentment, dosing ﬂexibility, outlook, value, and treatment
satisfaction) ranged from 0.73 to 0.86. Convergent and discrimi-
nant validity were assessed to determine scale acceptability for
further analysis. Goodness of ﬁt measures for the measurement
model (AMOS, version 7) were c2 = 50.8, df = 53, p = 0.559;
CFI = 1.00, GFI = 0.94, NFI = 0.92, RMSEA = 0.001, which
support the relationship between the data and the hypothesized
model. We anticipate recruiting more patients to ensure that the
data are consistent. CONCLUSION: Preliminary data from the
structural equation model revealed a 17-item instrument with 5
important domains (contentment with therapy, dosing ﬂexibility,
and outlook with respect to treatment satisfaction and value).
Further assessment and validation of the instrument is planned.
This novel instrument may provide greater knowledge regarding
the impact of psychological domains on treatment satisfaction
for patients with insomnia.
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OBJECTIVE: Multiple sclerosis (MS) is a chronic neurodegen-
erative disease which is the second most frequent cause of neu-
rological disability in young adults. The relapsing forms of the
disease are primarily treated with interferon beta or glatiramer
acetate. The aim of this study was to evaluate the level of satis-
faction of Spanish MS patients treated with the new formula-
tion of Avonex®, and whether this inﬂuences adherence.
METHODS: Data were obtained from the Global Adherence
Project, a multicenter open-label, post-marketing surveillance
study, performed in 17 centers in Spain. This included assessment
of the level of patient and neurologist satisfaction with the new
Avonex® formulation after 6 months of therapy. Two question-
naires were administered, one for patients and another for neu-
rologists. The study was approved by ethics committees and
patients signed informed consent. Descriptive statistical analyses
were performed. RESULTS: Of 257 patients included, 57
(22.2%) were treated with Avonex®; 55.4% of patients and
5.9% of neurologists were fully satisﬁed with the new formula-
tion. Most neurologists (88.3%) had intermediate satisfaction
scores. For patients and for neurologists, the most noteworthy
aspect of the change of formulation was the ease of use (73.2%
and 82.4%, respectively), followed by ease of storage (44.6%
and 29.4%), ease of injection (39.3% and 70.6%), less medica-
tion administered (25.0% and 11.8%) and for patients only,
better tolerability (8.9%). Adherence with Avonex® was 96.4%,
the highest among the therapies evaluated. CONCLUSION:
Both patients and neurologists were satisﬁed with Avonex® as
solution for injection. The most noteworthy aspect was the ease
of use. This seems to have a positive inﬂuence in the overall
patients’ adherence to the therapy.
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OBJECTIVE: Assess the types and number of health care pro-
fessionals seen by patients before diagnosis with dystonia and the
length of time from onset of symptoms. Describe the common
types of dystonias that are treated by the movement disorder
specialists and when appropriate, receive Botulinum Toxin Type
A treatment. METHODS: Patients with dystonia were asked to
complete a 19-question survey developed by the Canadian Move-
ment Disorders Survey Group. Questions included patient demo-
graphics, length of time from onset, number and types of
physicians seen, other diagnoses made, number treated with
Botulinum Toxin Type A and distance traveled. RESULTS: In this
interim analysis, 550 patients with dystonia were surveyed.
Majority of the patients were female (71%), traveling an average
of 99 km one-way. Most common dystonia diagnoses were
cervical dystonia (51%), hemifacial spasm (20%), and ble-
pharospasm (11%). Common diagnoses made prior to the dys-
tonia diagnoses were nerve/muscle problem (34%), stress/
psychological problem (39%), tremor (20%), ﬁbromyalgia
(19%), TMJ (16%), joint/tendon problem (15%) and spine
(11%). The average number of physicians seen before the dysto-
nia diagnosis was 3.2. Amongst these were family physician
(78%), neurologist (78%), movement disorder specialist (29%),
chiropractor (18%), eye care doctor (17%), neurosurgeon
(11%), and physiotherapist (15%). Most physicians who made
the dystonia diagnosis were neurologist (69%) and movement
disorder specialist (27%). The average time in years from onset
of symptoms to dystonia diagnosis were: cervical dystonia 5.2
(n = 278), blepharospasm 3.5 (n = 60), spasmodic dysphonia
4.0 (n = 10), limb dystonia 1.2 (n = 17), Meige syndrome 2.6
(n = 14), hemifacial spasm 3.2 (n = 112), generalized dystonia
8.0 (n = 8), oromandibular dystonia 5.0 (n = 8). 94% of patients
were treated with Botulinum Toxin Type A following their diag-
nosis with dystonia. CONCLUSION: The number of physicians
seen and length of time from onset to dystonia diagnosis is
substantial. Increased awareness of dystonia at the primary care
level may improve these rates.
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OBJECTIVE: Highly expensive disease modifying agents
(DMAs) were introduced in the 1990s to reduce the frequency of
relapse and to slow disease progression in patients with multiple
sclerosis (MS). However, the patterns of DMAs use remain
largely unknown. This study examines data from 2001–2005
population-based survey of MS patients to estimate duration of
DMA use and switching behavior, controlling for patient risk
factors. METHODS: We examined patterns of DMA use of 670
patients with relapsing remitting (RR) and secondary progressive
(SP) MS from the Sonya Slifka Longitudinal Multiple Sclerosis
Study. We generated Kaplan Meier covariate-adjusted estimates
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